Perspective Therapeutics (CATX) files updated corporate presentation covering four 212Pb radiopharmaceutical programs

Perspective Therapeutics, Inc.

Perspective Therapeutics filed an updated corporate presentation (Exhibit 99.1) dated October 1, 2026, signed by CFO Joel Sendek.
Presentation cites a combined $45B+ addressable solid tumor market for VMT-α-NET, VMT01, PSV359 and PSV594.
VMT-α-NET Phase 1/2a data in SSTR2+ neuroendocrine tumors targeted for ASCO 2026; safety data shown for 68 treated patients.
VMT01 preliminary anti-tumor activity observed at the 3.0 mCi dose in melanoma; PSV359 shows improved tumor retention against FAP-α.
CCK2R81 is highlighted as a potential first-in-class agent in medullary thyroid cancer and selected solid tumors.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.